HER2 as a prognostic and predictive marker for breast cancer.
about
A new model for ductal carcinoma in situ suggests strategies for treatmentA case-control study of the HER2 Ile655Val polymorphism in relation to risk of invasive breast cancerIdentifying patients at high risk of breast cancer recurrence: strategies to improve patient outcomesMolecular imaging of EGFR/HER2 cancer biomarkers by protein MRI contrast agentsModel-based analysis of HER activation in cells co-expressing EGFR, HER2 and HER3Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer.Breast Conserving Therapy: A surgical Technique where Little can Mean MorePrognostic implications of immunohistochemically detected YKL-40 expression in breast cancer.A novel class of small molecule inhibitors of Hsp90.Targeted molecular imaging in oncology: focus on radiation therapy.Clinical Relevance of Liver Kinase B1(LKB1) Protein and Gene Expression in Breast CancerCombinatorial experimental protocols for Erbicin-derived immunoagents and Herceptin.[18F]FBEM-Z(HER2:342)-Affibody molecule-a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography.Novel HER2 aptamer selectively delivers cytotoxic drug to HER2-positive breast cancer cells in vitroAberrant c-erbB2 expression in cell clusters overlying focally disrupted breast myoepithelial cell layers: a trigger or sign for emergence of more aggressive cell clones?Cutaneous vasculitis in breast cancer treated with chemotherapy.HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives.Cardiac tolerability of concurrent administration of trastuzumab and anthracycline-based regimen as adjuvant chemotherapy for breast cancer.ATM mutations and E-cadherin expression define sensitivity to EGFR-targeted therapy in colorectal cancer.Evaluation of human epidermal growth factor receptor 2 in breast cancer with a novel specific aptamer.Incorporating gold nanoclusters and target-directed liposomes as a synergistic amplified colorimetric sensor for HER2-positive breast cancer cell detectionVisible to Near-Infrared Fluorescence Enhanced Cellular Imaging on Plasmonic Gold Chips.Cationic Polymer Modified Mesoporous Silica Nanoparticles for Targeted SiRNA Delivery to HER2+ Breast Cancer.Breast cancer mortality among patients attending a cancer hospital, Vitoria, ES.Absence of c-KIT and members of the epidermal growth factor receptor family in refractory germ cell cancer.Multivariate analysis of survival in inflammatory breast cancer: impact of intensity of chemotherapy in multimodality treatment.Aberrant expression of CD227 is correlated with tumor characteristics and invasiveness of breast carcinoma.Clinicopathologic features of breast cancer patients with type 2 diabetes mellitus in southwest of China.Whole exome sequencing to identify genetic markers for trastuzumab-induced cardiotoxicity.Trastuzumab, non-pegylated liposomal-encapsulated doxorubicin and paclitaxel in the neoadjuvant setting of HER-2 positive breast cancer.Prognosis significance of HER2 status and TACC1 expression in patients with gastric carcinoma.
P2860
Q24802734-A1E41369-4E22-4B98-B3C0-254A063605A3Q24810260-FE34C6A6-8FD2-47A6-8AF1-A769BBBB3330Q26778675-D8BF30E5-D2C3-40C8-B536-E816B86A87FCQ28304646-45501F48-01E7-40A1-BB6C-3C7DB6BC43CEQ31129446-8D04BC31-865A-41F0-ACB5-CDF03BA743FFQ34998307-1737B5C2-24CA-4FB4-B34D-99E8985CB872Q35336219-65B75D21-EFDA-4BA7-B541-196D196B550AQ35647254-2A9AE0C9-1F20-40FB-A6F3-7C7D8B4FE9B7Q35764444-06B19151-D19A-4284-B5FB-3B43EE0FF9F1Q36528175-5BB6C91C-DA5D-422A-9D24-4BA1926212BCQ36579447-2319F157-E21F-494D-AA2F-A9C3732F2AC9Q36610604-D7A25AB8-67F3-4907-A3A4-424395240115Q36627997-D3C5F4C0-79DE-4B14-8407-5D25F287A423Q36641436-BC8318F2-0D2B-4D95-A61F-7C0AF808A001Q36846399-AD398FC6-B432-465D-8C3C-68933081388CQ36963933-D3D95256-658C-4F61-A352-169D7750114EQ37708897-7A1171CC-ABC1-4C2A-ACDA-2591DF172169Q37716211-4CB1FAED-D184-4AF7-B7A0-07595893C32CQ37725589-977C2F48-4C73-40A6-BF8C-5C40A789562DQ37737816-6FFE9251-A3E1-4606-B156-68C854DEBA5EQ37738222-6D9C5679-8AD3-4DEE-BE43-11AA85628FF2Q38811907-EB4FC774-0027-40A0-B50C-9FF52C6B9078Q42429773-22535243-1C16-4342-BDC7-299F047DD47EQ43666335-9DF0EB64-57A1-49AB-8330-4E8A0EF8CD14Q44068928-A8316055-2306-402E-81EB-36ADEEFE7213Q44788997-417DA321-FE87-48DE-BAAA-5790AD071415Q45827896-C2B9B7B0-6F7D-4CA3-A223-06AC7E34C1F2Q46098998-A5059CE2-CADB-47ED-8AE7-B532A64F5D71Q47286758-00BB423B-F52B-4C93-9713-9DBDD80D86C6Q47863782-6AB3A1BA-BF34-4F58-A2DF-1C55B25BA5B3Q54316753-4349C684-C659-40B2-9797-70DDE05B3A49
P2860
HER2 as a prognostic and predictive marker for breast cancer.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
HER2 as a prognostic and predictive marker for breast cancer.
@ast
HER2 as a prognostic and predictive marker for breast cancer.
@en
HER2 as a prognostic and predictive marker for breast cancer.
@nl
type
label
HER2 as a prognostic and predictive marker for breast cancer.
@ast
HER2 as a prognostic and predictive marker for breast cancer.
@en
HER2 as a prognostic and predictive marker for breast cancer.
@nl
prefLabel
HER2 as a prognostic and predictive marker for breast cancer.
@ast
HER2 as a prognostic and predictive marker for breast cancer.
@en
HER2 as a prognostic and predictive marker for breast cancer.
@nl
P2093
P356
P1433
P1476
HER2 as a prognostic and predictive marker for breast cancer.
@en
P2093
P356
10.1093/ANNONC/12.SUPPL_1.S23
P478
12 Suppl 1
P577
2001-01-01T00:00:00Z